海王生物(000078.SZ):子公司將獲得廣東省科技創新戰略專項資金補助500萬元
格隆匯11月20日丨海王生物(000078.SZ)公佈,公司於近日收到公司全資子公司深圳海王醫藥科技研究院有限公司(“海王研究院”)通知獲悉:
根據廣東省財政廳下發《關於安排2019年度省科技創新戰略專項資金(省技術創新中心等)的通知》(粵財科教〔2019〕161號),海王研究院將獲得2019年廣東省科技創新戰略專項資金(新建新型研發機構)補助,補助資金為人民幣500萬元,預計於本年度內到賬。
2017年,海王研究院獲批認定為廣東省新型研發機構。根據新型研發機構管理辦法,對在研究開發、成果轉化、科研設施條件建設、高端人才集聚和培養、科技企業孵化等方面業績突出的省級新型研發機構給予建設支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.